Source comparison
BPC 157 vs BPC-157: Naming Variations Across Suppliers
The table below compares how different naming conventions appear across research literature, commercial suppliers, and regulatory filings—demonstrating that the hyphen signals formatting preference, not molecular difference. BPC 157 Early Zagreb research publi
This comparison does not assign a generated winner or score.
- The table below compares how different naming conventions appear across research literature, commercial suppliers, and regulatory filings—demonstrating that the hyphen signals formatting preference, not molecular difference.
- BPC 157
- Early Zagreb research publications, European pharmacology journals
- 15-amino-acid synthetic peptide
- Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val
- Identical to BPC-157; no structural or functional difference
- BPC-157
- Commercial peptide suppliers, PubMed-indexed studies post-2010
- Identical to BPC 157; hyphen is stylistic only
- Bepecin
- Proprietary branded name used by specific research institutions
- Trade name for BPC 157; same compound with institution-specific branding
- PL 14736
- Alternative catalog identifier in some European peptide databases
- Catalog code for BPC 157; references same Zagreb-derived sequence
- Some suppliers use "BPC-157" exclusively because it appears more frequently in recent PubMed-indexed studies—purely a search optimization tactic. Others maintain "BPC 157" to align with the original Zagreb publications from the 1990s. Neither choice indicates higher purity, better synthesis, or superior research outcomes. What does matter: whether the supplier can provide third-party HPLC verification of the 15-amino-acid sequence and confirm storage at −20°C before shipment. A supplier offering "BPC-157" at 95% purity is objectively inferior to one offering "BPC 157" at 98% purity, regardless of hyphen presence.